CN103919887A - Traditional Chinese medicinal composition for treating tumor and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating tumor and preparation method thereof Download PDFInfo
- Publication number
- CN103919887A CN103919887A CN201410088187.5A CN201410088187A CN103919887A CN 103919887 A CN103919887 A CN 103919887A CN 201410088187 A CN201410088187 A CN 201410088187A CN 103919887 A CN103919887 A CN 103919887A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- herba
- radix
- medicine composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicinal composition for treating tumor. The traditional Chinese medicinal composition is composed of the following traditional Chinese medicines: root of large-flowered skullcap, Artemisia capillaries, cape jasmine, abrus cantoniensis hance, red sage root, Chinese magnoliavine, wild chrysanthemum flower, radix sophorae flavescentis, desmodium and plantago. The composition provided by the invention has a curative effect of treating tumor, and the effect of the composition are better than that of the prior art.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition for the treatment of tumor and preparation method thereof.
Background technology
Tumor (tumor, neoplasm), be body under the effect of various tumorigenesis factor, the cell of local organization has lost the normal regulation to its growth on gene level, causes paraplasm and the neoplasm that forms.This neoplasm often forms local lump, thereby gains the name.
Tumor is a kind of commonly encountered diseases, frequently-occurring disease, and wherein malignant tumor is the class disease that current harm humans health is the most serious.In more American-European countries, the mortality rate of malignant tumor is only second to cardiovascular system diseases and occupies second.According to China's Development of Health Service situation statistical communique in 1992, urban area Malignant Tumors among Residents mortality rate occupies first of the cause of the death, is 123.92/10 ten thousand, and in base, male is 151.08/10 ten thousand, and women is 95.12/10 ten thousand.Rural area Malignant Tumors among Residents mortality rate occupies cause of the death second, is 101.39/10 ten thousand.Wherein male is 125.79/10 ten thousand, and women is 78.85/10 ten thousand.Along with the process of China's aged tendency of population, urban population ratio increases year by year in addition, and cities and towns commercial production develops rapidly, environmental pollution is day by day serious, the bad life habits such as smoking are quite general, if do not take positive communication and education measure, the hazardness of malignant tumor also will increase day by day.The most common and serious tumor of hazardness of China is pulmonary carcinoma, nasopharyngeal carcinoma, the esophageal carcinoma, gastric cancer, colorectal cancer, hepatocarcinoma, breast carcinoma, cervical cancer, leukemia and lymphoma etc.Particularly lung cancer incidence has obvious increase, significant in recent years.Etiology, pathogenesis and the control thereof of these tumors, all should be the emphasis of China's tumor research.
Existing Therapeutic Method has operation, chemotherapy etc., and these methods have side effect in various degree, and in order to pursue better effect, Chinese medicine is having unique curative effect aspect treatment cancer.
Relate to the relevant report comparatively approaching with technical scheme of the present invention as follows:
CN201210478993.4(publication number is CN103007191A) relate to a kind of Chinese medicine composition for the treatment of jaundice, its raw material of Chinese medicine by following weight portion forms: Herba Artemisiae Scopariae 30-50 part, Fructus Gardeniae 10-20 part, Herba Dendrobii 10-20 part, Radix Curcumae 10-20 part, Endothelium corneum 10-20 part, Rhizoma Atractylodis Macrocephalae (parched) 10-30 part, Semen Coicis 20-40 part, Radix Angelicae Sinensis 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Radix Et Rhizoma Rhei 5-15 part, Fructus Hordei Germinatus (parched) 20-40 part, Herba Lysimachiae 20-40 part, Rhizoma Polygoni Cuspidati 5-15 part, Herba Sedi 10-20 part, Herba Abri 10-20 part, Radix Glycyrrhizae 3-9 part, Radix Paeoniae Rubra 30-50 part, Radix Paeoniae Alba 10-30 part, Herba Silybi mariani 20-40 part.
CN200610149041.2(publication number is CN101190324A) relate to people and treat a kind of external-use tincture Chinese medicine of hepatitis B, it is characterized in that by Squama Manis, eupolyphaga, Scorpio, Rhizoma Gastrodiae, Herba Abri, Herba Rabdosiae Lophanthoidis, the Radix Astragali, Radix Clematidis, Fructus Schisandrae Chinensis, Bufo siccus, Adeps Bovis seu Bubali, Flos Carthami, Radix Angelicae Sinensis, Radix Scrophulariae, Herba Artemisiae Scopariae, Polyporus, Herba Sedi, Radix Scutellariae, Cortex Magnoliae Officinalis, Radix Curcumae, Fructus Gardeniae, Cortex Cinnamomi, Radix Gentianae, Rhizoma Polygoni Cuspidati, Caulis Akebiae, the prescription drug of the compositions such as Rhizoma Alismatis adds the soaking in Chinese liquor 30 days of ten times after pulverizing, taking liquid is put on the skin in position, hepatic region, just can reach the object of curing hepatitis B.
CN03100806.2(publication number is CN1513487A) the compound recipe Herba abri capsule that is used for the treatment of liver and gall diseases is disclosed, wherein contain by weight Herba Abri 240, Herba Artemisiae Scopariae 40, Fructus Gardeniae 32, the Radix Paeoniae Alba 40, Fructus Schisandrae Chinensis 40, Radix Notoginseng 16, Fructus Lycii 16, artificial Calculus Bovis 4, Margarita layer powder 4.Its manufacture method is the alcohol steep with 70 quality % by Fructus Schisandrae Chinensis, collects filtrate.
And on market, sell at present also only have Guanule contg. ' Jigucao ball, as: in drug standard WS-11021 (ZD-1021)-2002, disclose a kind of Guanule contg. ' Jigucao ball, its prescription is Os Gallus domesticus list 2345g, Herba Artemisiae Scopariae 2345g, Herba Hyperici Japonici 2345g, Radix Rhodomyrti 2345g, Herba artemisiae lactiflorae 2345g, Radix Zanthoxyli Avicennae 3905g.
Existing kind, the effect for the treatment of tumor is not remarkable, and inventor has summed up technical scheme of the present invention in clinical practice.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of tumor.
The Chinese medicine composition for the treatment of tumor provided by the invention, is made up of following Chinese medicine: Radix Scutellariae, Herba Artemisiae Scopariae, Fructus Gardeniae, Herba Abri, Radix Salviae Miltiorrhizae, Fructus Schisandrae Chinensis, Flos Chrysanthemi Indici, Radix Sophorae Flavescentis, Herba Lysimachiae and Herba Plantaginis.
Concrete, described Chinese medicine composition is made up of the Chinese medicine of following weight portion: Radix Scutellariae 150-500 part, Herba Artemisiae Scopariae 500-1500 part, Fructus Gardeniae 150-500 part, Herba Abri 150-500 part, Radix Salviae Miltiorrhizae 150-500 part, Fructus Schisandrae Chinensis 150-500 part, Flos Chrysanthemi Indici 150-500 part, Radix Sophorae Flavescentis 150-500 part, Herba Lysimachiae 150-500 part and Herba Plantaginis 150-500 part.
Preferably, described Chinese medicine composition is made up of the Chinese medicine of following weight portion: Radix Scutellariae 250-400 part, Herba Artemisiae Scopariae 750-1250 part, Fructus Gardeniae 250-400 part, Herba Abri 250-400 part, Radix Salviae Miltiorrhizae 150-300 part, Fructus Schisandrae Chinensis 150-300 part, Flos Chrysanthemi Indici 250-400 part, Radix Sophorae Flavescentis 250-400 part, Herba Lysimachiae 250-400 part and Herba Plantaginis 250-400 part.
Further preferably, described Chinese medicine composition is made up of the Chinese medicine of following weight portion: 333 parts of 333 parts of Radix Scutellariaes, 999 parts of Herba Artemisiae Scopariaes, 333 parts of Fructus Gardeniaes, 333 parts of Herba Abris, 266 parts of Radix Salviae Miltiorrhizaes, 266 parts of Fructus Schisandrae Chinensis, 333 parts of Flos Chrysanthemi Indicis, 333 parts of Radix Sophorae Flavescentiss, 333 parts of Herba Lysimachiaes and Herba Plantaginiss.
In above-mentioned Chinese medicine composition:
Described weight portion can be the known unit of weights of field of medicaments such as μ g, mg, g, kg, can be also its multiple, as 1/10,1/100,10 times, 100 times etc.
Described Fructus Schisandrae Chinensis is preferably the Radix Schisandrae Bicoloris of processed with wine.
The present invention also provides the preparation method of above-mentioned Chinese medicine composition, the method comprises the following steps: take each composition according to proportioning, then decoct with water 1-3 time, each 1-3 hour, collecting decoction, filter, it is 1.25-1.35(50 DEG C that filtrate decompression is concentrated into relative density) clear paste, dry, to obtain final product.
The present invention also provides the preparation containing above-mentioned Chinese medicine composition, and described preparation is made up separately of Chinese medicine composition or is made up of Chinese medicine composition and pharmaceutically acceptable carrier.
Described preparation is tablet, capsule, pill, granule or powder.Described pharmaceutically acceptable carrier refers to the pharmaceutical carrier of pharmaceutical field routine, is selected from one or more in filler, binding agent, disintegrating agent, lubricant, solubilizing agent, suspending agent, wetting agent, pigment, essence, solvent, surfactant or correctives.
Described filler is selected from starch, pregelatinized Starch, dextrin, glucose, sucrose, lactose, lactose, microcrystalline Cellulose, mannitol, sorbitol or xylitol, preferably sorbitol, microcrystalline Cellulose, lactose or pregelatinized Starch;
Described disintegrating agent is selected from cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium or starch, preferably polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose or carboxymethyl starch sodium;
Described lubricant is selected from magnesium stearate, Pulvis Talci, micropowder silica gel, PEG4000, PEG6000, sodium laurylsulfate, preferably magnesium stearate, Pulvis Talci;
Described binding agent is selected from sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, polyvidone, starch slurry, sucrose, Icing Sugar, rubber cement, gelatin, Polyethylene Glycol, preferably hydroxypropyl methylcellulose, polyvidone;
Described solubilizing agent is selected from sodium hydroxide, potassium hydroxide, sodium bicarbonate, meglumine, 1B, L-arginine, preferably sodium hydroxide, meglumine;
Described suspending agent is selected from micropowder silica gel, Cera Flava, cellulose, solid polyethylene glycol;
Described wetting agent is selected from glycerol, tween 80, ethyoxyl castor oil hydrogenated or lecithin;
Described solvent is selected from ethanol, liquid polyethylene glycol, isopropyl alcohol, tween 80, glycerol, propylene glycol or vegetable oil, and described vegetable oil is selected from soybean oil, Oleum Ricini, Oleum Arachidis hypogaeae semen, mediation wet goods;
Described surfactant is selected from smooth or Polysorbate (tween) of dodecylbenzene sodium sulfonate, stearic acid, Pluronic F68, fatty acid Pyrusussuriensis etc.;
Described correctives is selected from aspartame, Sucralose, essence, steviosin, acesulfame potassium, citric acid or saccharin sodium.
The present invention also provides above-mentioned composition or the application of preparation in the medicine of preparation treatment tumor.
The Chinese medicine composition for the treatment of hepatopathy provided by the invention has the following advantages:
1, Fang Xie:
Radix Scutellariae: heat clearing and damp drying, eliminating fire and detoxication.
Herba Artemisiae Scopariae: heat clearing away, jaundice eliminating, function of gallbladder promoting.
Fructus Gardeniae: pathogenic fire purging relieving restlessness; Clearing away heat-damp and promoting diuresis; Removing pathogenic heat from blood and toxic substance from the body.
Herba Abri: clearing away heat-damp and promoting diuresis, eliminating stasis to stop pain.
Radix Salviae Miltiorrhizae: blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind.
Radix Schisandrae Bicoloris (processed with wine): the nourishing kidney of astringing the lung, the arresting sweating that promotes the production of body fluid, arresting seminal emission antidiarrheal.
Flos Chrysanthemi Indici: heat-clearing and toxic substances removing; Dispelling wind suppressing the hyperactive liver.
Radix Sophorae Flavescentis: heat clearing and damp drying.
Herba Lysimachiae: clearing away heat-damp and promoting diuresis, subduing swelling and detoxicating.
Herba Plantaginis: clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.Function cures mainly: clearing away heat-damp and promoting diuresis, promoting the function of the gallbladder to alleviate jaundice.For syndrome of dampness-heat of liver and gallbladder, see have that abdominal distension and anorexia is detested oil, felt sick, xerostomia, greasy fur, icteric sclera, yellowish complexion, yellowish body, yellowish or reddish urine.
Herba Artemisiae Scopariae, Herba Plantaginis clearing away heat-damp and promoting diuresis in prescription, promoting the function of the gallbladder to alleviate jaundice, draws damp and hot heresy and goes out from urine; Radix Scutellariae, Fructus Gardeniae, Radix Sophorae Flavescentis, Flos Chrysanthemi Indici, Herba Lysimachiae clearing away heat-damp and expelling toxic material; Radix Salviae Miltiorrhizae, Herba Abri, blood stasis-eliminating and stagnation-dissipating pain relieving, the Radix Schisandrae Bicoloris nourishing kidney of astringing the lung.
All medicines coordinate, not only dampness removing heat clearing away, and promoting the function of the gallbladder to alleviate jaundice, and harmonizing the functional activities of vital QI, heat clearing away expelling pathogenic factors from the exterior, makes to stop up the damp and hot malicious heresy of holding back and disappears.
Energy heat clearing and damp drying, eliminating fire and detoxication, by external the removing of liver inner virus residue, reaches liver function normalization;
Blood circulation promoting and blood stasis dispelling, strengthening vital QI to eliminate pathogenic factors, gets through liver internal congestion blood vessel, and hepatocyte obtains nutrition, and hepatocyte is regenerated gradually, reaches liver function normalization.
2, experimental result shows: compositions provided by the invention is truly having curative effect aspect treatment tumor, and effect is better than prior art.
3, take safety, have no side effect.
Detailed description of the invention
Following examples are used for illustrating the present invention, but are not used for limiting the scope of the invention.
Embodiment 1: the Chinese medicine composition for the treatment of tumor
1, composition: Radix Scutellariae 333g, Herba Artemisiae Scopariae 999g, Fructus Gardeniae 333g, Herba Abri 333g, Radix Salviae Miltiorrhizae 266g, Radix Schisandrae Bicoloris (processed with wine) 266g, Flos Chrysanthemi Indici 333g, Radix Sophorae Flavescentis 333g, Herba Lysimachiae 333g, Herba Plantaginis 333g.
2, preparation method: take each composition according to proportioning, the decocting that then adds 8 times of amounts of Chinese medicine gross weight boils 2 times, each 2 hours, collecting decoction, filter, it is 1.25-1.35(50 DEG C that filtrate decompression is concentrated into relative density) clear paste.
3, granule: clear paste 1kg, dextrin 1kg, sucrose 2kg, granulation, subpackage.
Embodiment 2: the Chinese medicine composition for the treatment of tumor
1, composition: Radix Scutellariae 250g, Herba Artemisiae Scopariae 750g, Fructus Gardeniae 250g, Herba Abri 250g, Radix Salviae Miltiorrhizae 150g, Radix Schisandrae Bicoloris (processed with wine) 150g, Flos Chrysanthemi Indici 250g, Radix Sophorae Flavescentis 400g, Herba Lysimachiae 400g, Herba Plantaginis 400g.
2, preparation method: take each composition according to proportioning, the decocting that then adds 10 times of amounts of Chinese medicine gross weight boils 2 times, and the time is respectively 2 hours, 1.5 hours, collecting decoction, filter, it is 1.25-1.35(50 DEG C that filtrate decompression is concentrated into relative density) clear paste.
3, preparation: 1.5 parts of qinghuo reagents, add 1 part, dextrin, 3 parts of sucrose, granulation, dry, make 1000g.
Embodiment 3: the Chinese medicine composition for the treatment of tumor
1, composition: Radix Scutellariae 400g, Herba Artemisiae Scopariae 1250g, Fructus Gardeniae 400g, Herba Abri 400g, Radix Salviae Miltiorrhizae 300g, Radix Schisandrae Bicoloris (processed with wine) 150g, Flos Chrysanthemi Indici 400g, Radix Sophorae Flavescentis 250g, Herba Lysimachiae 250g, Herba Plantaginis 250g.
2, preparation method: take each composition according to proportioning, the decocting that then adds 10 times of amounts of Chinese medicine gross weight boils 2 times, and the time is respectively 2 hours, 1.5 hours, collecting decoction, filter, it is 1.25-1.35(50 DEG C that filtrate decompression is concentrated into relative density) clear paste.
3, preparation: 1.5 parts of qinghuo reagents, add 1 part, dextrin, 3 parts of sucrose, granulation, dry, make 1000g.
Embodiment 4: the Chinese medicine composition for the treatment of tumor
1, composition: Radix Scutellariae 150g, Herba Artemisiae Scopariae 1500g, Fructus Gardeniae 150g, Herba Abri 500g, Radix Salviae Miltiorrhizae 500g, Radix Schisandrae Bicoloris (processed with wine) 150g, Flos Chrysanthemi Indici 500g, Radix Sophorae Flavescentis 150g, Herba Lysimachiae 500g, Herba Plantaginis 500g.
2, preparation method: take each composition according to proportioning, the decocting that then adds 10 times of amounts of Chinese medicine gross weight boils 2 times, and the time is 2 hours, collecting decoction, filter, it is 1.25-1.35(50 DEG C that filtrate decompression is concentrated into relative density) clear paste.
3, preparation: 1 part of qinghuo reagent, 0.5 part of microcrystalline Cellulose, 0.3 part of lactose, 0.05 part of polyvinylpolypyrrolidone, direct compression.
Embodiment 5: the Chinese medicine composition for the treatment of tumor
1, composition: Radix Scutellariae 500g, Herba Artemisiae Scopariae 500g, Fructus Gardeniae 500g, Herba Abri 150g, Radix Salviae Miltiorrhizae 450g, Radix Schisandrae Bicoloris (processed with wine) 150g, Flos Chrysanthemi Indici 150g, Radix Sophorae Flavescentis 250g, Herba Lysimachiae 450g, Herba Plantaginis 450g.
2, preparation method: take each composition according to proportioning, the decocting that then adds 10 times of amounts of Chinese medicine gross weight boils 2 times, and the time is respectively 2 hours, 1.5 hours, collecting decoction, filter, it is 1.25-1.35(50 DEG C that filtrate decompression is concentrated into relative density) clear paste.
3, preparation: 1.5 parts of qinghuo reagents, add 1 part, dextrin, 3 parts of sucrose, granulation, dry, make 1000g.
Experimental example 1: effect experiment
1, experiment material
1.1 medicines and reagent: newborn calf serum (Hangzhou Ilex purpurea Hassk.[I.chinensis Sims company), MEM culture fluid (Gibco company), RPMI1640 culture fluid (Gibco company), pancreatin (Gibco company), Boxing bio tech ltd, MTT(Zhengzhou); The yellow granule of compound recipe mattress (preparation that embodiment 1-5 provides); Guanule contg. ' Jigucao granule (Guangdong Yi Hetang pharmaceutical Co. Ltd, the accurate word Z44023179 of traditional Chinese medicines.
1.2 for trying cell: human esophagus cancer cell (EC-1), human brain astrocytoblast oncocyte (U87MG), human lung carcinoma cell (A549), human breast cancer cell (MCF-7), human cervical carcinoma cell (Hela), the former leukaemia of the chronic marrow of people (K562), human liver cancer cell (Hep G
2) provide by Shanghai Chinese Academy of Sciences cell bank.
Above cell is containing 10%(percentage by volume) newborn calf serum, 100U/mL penicillin, grows in the MEM of 100U/mL streptomycin or RPMI1640 culture fluid, at the temperature of 37 DEG C, 5%(volume fraction) CO
2incubator in cultivate, 2 days change a culture fluid, when culture bottle is paved with, go down to posterity with 2.5g/L trypsinization, cell culture is to logarithmic (log) phase.
1.3 instruments: CO2 incubator (MCO-15AC, SANYO), automatic microplate reader (Mk3, U.S. Thermro produces), inverted microscope (XDS-200D, Shanghai Cai Kang optical instrument company limited).
1.4 statistical method: adopt SPSS-12.0 to carry out statistical procedures, measurement data all uses x ± s to represent.
2, experimental technique
The yellow granule of 2.1 preparation compound recipe mattress and Guanule contg. ' Jigucao particle solution: add normal saline and be mixed with the solution of 1.0g/mL, for subsequent use.
2.2MTT method is measured the yellow granule of compound recipe mattress to human esophagus cancer cell (EC-1), human brain astrocytoblast oncocyte (U87MG), human lung carcinoma cell (A549), human breast cancer cell (MCF-7), human cervical carcinoma cell (Hela), the former leukaemia of the chronic marrow of people (K562), human liver cancer cell (Hep G
2) inhibitory action of cell: get the above-mentioned cell that is cultured to exponential phase, about 3-5 × 10 of cell counting
4individual/mL(K562 cell is 2.5 × 10
5individual/mL), be inoculated in 96 orifice plates every hole liquid 100 μ L, (except K562 cell) stock solution of inclining after cell attachment; Then add the culture fluid of the hyclone that contains 0.3% volume fraction, hungry cultivation; After 24h, change culture fluid, and add the yellow particle solution of compound recipe mattress (the method preparation of embodiment 1), be mixed with respectively 0.1g/mL, 0.3g/mL, 0.5g/mL, 0.7g/mL, 0.8g/mL, 0.9g/mL and seven variable concentrations of 1.0g/mL as mensuration group, normal cell and isocyatic Shenyi capsule solution (every group arranges 6 multiple holes) is as a control group set simultaneously, continues to cultivate 24h; Then every hole adds 20 μ L MTT, and all liq is removed in 4h hypsokinesis, adds 150 μ LDMSO, makes dissolution of solid, leaves standstill 0.5h at 37 DEG C of temperature; Under the wavelength of 570nm, detect reference under 630nm wavelength by automatic microplate reader; Calculate GLG to above-mentioned cell half-inhibition concentration (IC
50).Suppression ratio=(1-mensuration group OD value/Normal group OD value) × 100%.
According to the method described above, repeat experiment, the method preparation that the yellow granule of compound recipe mattress is wherein embodiment 2-5.
3, result: as shown in table 1.
Half-inhibition concentration (the IC of table 1:GLG to various tumor cells
50)
Note: △ P<0.05 compared with positive controls, △ △ P<0.01
Table 1 result shows: the yellow granule of compound recipe mattress that embodiment 1 provides all has stronger cytotoxicity to EC-1 cell, U87MG cell, Hela cell, K562 cell, MCF-7 cell, Hep G2 cell, compared with positive controls, the yellow granule of compound recipe mattress is suitable with the yellow granule effect of compound recipe mattress to EC-1 cytosis, strong not as good as Guanule contg. ' Jigucao granule to A549 cytosis, all strong compared with Guanule contg. ' Jigucao granule to U87MG cell, Hela cell, K562 cell, MCF-7 cell, Hep G2 killing functions of immunocytes.
Equally, the yellow granule effect of compound recipe mattress that embodiment 2-5 provides is with embodiment 1.
Result shows: compositions provided by the invention truly has curative effect in treatment tumor especially brain astrocytoblast tumor, pulmonary carcinoma, cervical cancer, the esophageal carcinoma, the former leukemia of chronic marrow, breast carcinoma and liver cancer, and effect is better than prior art.
Although, above use general explanation, detailed description of the invention and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (10)
1. treat a Chinese medicine composition for tumor, formed by following Chinese medicine: Radix Scutellariae, Herba Artemisiae Scopariae, Fructus Gardeniae, Herba Abri, Radix Salviae Miltiorrhizae, Fructus Schisandrae Chinensis, Flos Chrysanthemi Indici, Radix Sophorae Flavescentis, Herba Lysimachiae and Herba Plantaginis.
2. Chinese medicine composition according to claim 1, it is characterized in that, described Chinese medicine composition is made up of the Chinese medicine of following weight portion: Radix Scutellariae 150-500 part, Herba Artemisiae Scopariae 500-1500 part, Fructus Gardeniae 150-500 part, Herba Abri 150-500 part, Radix Salviae Miltiorrhizae 150-500 part, Fructus Schisandrae Chinensis 150-500 part, Flos Chrysanthemi Indici 150-500 part, Radix Sophorae Flavescentis 150-500 part, Herba Lysimachiae 150-500 part and Herba Plantaginis 150-500 part.
3. Chinese medicine composition according to claim 1, it is characterized in that, described Chinese medicine composition is made up of the Chinese medicine of following weight portion: Radix Scutellariae 250-400 part, Herba Artemisiae Scopariae 750-1250 part, Fructus Gardeniae 250-400 part, Herba Abri 250-400 part, Radix Salviae Miltiorrhizae 150-300 part, Fructus Schisandrae Chinensis 150-300 part, Flos Chrysanthemi Indici 250-400 part, Radix Sophorae Flavescentis 250-400 part, Herba Lysimachiae 250-400 part and Herba Plantaginis 250-400 part.
4. Chinese medicine composition according to claim 1, it is characterized in that, described Chinese medicine composition is made up of the Chinese medicine of following weight portion: 333 parts of 333 parts of Radix Scutellariaes, 999 parts of Herba Artemisiae Scopariaes, 333 parts of Fructus Gardeniaes, 333 parts of Herba Abris, 266 parts of Radix Salviae Miltiorrhizaes, 266 parts of Fructus Schisandrae Chinensis, 333 parts of Flos Chrysanthemi Indicis, 333 parts of Radix Sophorae Flavescentiss, 333 parts of Herba Lysimachiaes and Herba Plantaginiss.
5. according to the Chinese medicine composition described in claim 1-4 any one, it is characterized in that the Radix Schisandrae Bicoloris that described Fructus Schisandrae Chinensis is processed with wine.
6. prepare the method for the Chinese medicine composition described in claim 1-5 any one for one kind, it is characterized in that, the method comprises the following steps: take each composition according to proportioning, then decoct with water 1-3 time each 1-3 hour, collecting decoction, filter, filtrate decompression is concentrated into the clear paste that 50 DEG C of relative densities are 1.25-1.35, dry, to obtain final product.
7. containing the preparation of the Chinese medicine composition described in claim 1-5 any one, it is characterized in that, described preparation is made up separately of Chinese medicine composition or is made up of Chinese medicine composition and pharmaceutically acceptable carrier.
8. preparation according to claim 7, is characterized in that, described preparation is tablet, capsule, pill, granule or powder.
9. preparation according to claim 7, it is characterized in that, described pharmaceutically acceptable carrier refers to the pharmaceutical carrier of pharmaceutical field routine, is selected from one or more in filler, binding agent, disintegrating agent, lubricant, solubilizing agent, suspending agent, wetting agent, pigment, essence, solvent, surfactant or correctives.
10. the application of the preparation described in the compositions described in claim 1-5 any one or claim 7-9 any one in the medicine of preparation treatment tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410088187.5A CN103919887B (en) | 2014-03-11 | 2014-03-11 | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410088187.5A CN103919887B (en) | 2014-03-11 | 2014-03-11 | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103919887A true CN103919887A (en) | 2014-07-16 |
| CN103919887B CN103919887B (en) | 2015-11-18 |
Family
ID=51138429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410088187.5A Active CN103919887B (en) | 2014-03-11 | 2014-03-11 | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919887B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587108A (en) * | 2015-02-06 | 2015-05-06 | 席新进 | Traditional Chinese medicine composition for treating liver tumors |
| CN104623222A (en) * | 2015-03-16 | 2015-05-20 | 徐若曾 | Traditional Chinese medicine composition with effects of clearing away heat and toxic materials for treating breast cancer and preparation method thereof |
| CN104758464A (en) * | 2015-03-16 | 2015-07-08 | 徐若曾 | Blood-activating and stasis-resolving medicament for treating breast cancer and preparation method thereof |
| CN105326975A (en) * | 2015-12-04 | 2016-02-17 | 钱玲科 | Traditional Chinese medicine extract and application of same to preparation of drug for treating cervical carcinoma |
| CN106362114A (en) * | 2016-10-13 | 2017-02-01 | 南宁多灵生物科技有限公司 | Medicine for treating breast cancer |
| CN106729158A (en) * | 2017-02-21 | 2017-05-31 | 上海世道健康科技有限公司 | It is a kind of to treat Chinese medicine composition of osteocarcinoma and preparation method thereof |
| CN111184835A (en) * | 2020-04-09 | 2020-05-22 | 喻小兰 | A pharmaceutical composition prepared from baicalein for treating cervical cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238981A (en) * | 1998-06-16 | 1999-12-22 | 张志轩 | Medicine for preventing and treating tumor and preparation method thereof |
| CN1364589A (en) * | 2001-01-19 | 2002-08-21 | 王淑玲 | Medicine for curing carcinoma of stomach |
| CN101524436A (en) * | 2008-03-06 | 2009-09-09 | 北京中科仁和科技有限公司 | Chinese medicinal composition for treating lung cancer |
| CN102357211A (en) * | 2011-04-25 | 2012-02-22 | 周琼 | Traditional Chinese medicine composition for curing cancers |
-
2014
- 2014-03-11 CN CN201410088187.5A patent/CN103919887B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238981A (en) * | 1998-06-16 | 1999-12-22 | 张志轩 | Medicine for preventing and treating tumor and preparation method thereof |
| CN1364589A (en) * | 2001-01-19 | 2002-08-21 | 王淑玲 | Medicine for curing carcinoma of stomach |
| CN101524436A (en) * | 2008-03-06 | 2009-09-09 | 北京中科仁和科技有限公司 | Chinese medicinal composition for treating lung cancer |
| CN102357211A (en) * | 2011-04-25 | 2012-02-22 | 周琼 | Traditional Chinese medicine composition for curing cancers |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587108A (en) * | 2015-02-06 | 2015-05-06 | 席新进 | Traditional Chinese medicine composition for treating liver tumors |
| CN104623222A (en) * | 2015-03-16 | 2015-05-20 | 徐若曾 | Traditional Chinese medicine composition with effects of clearing away heat and toxic materials for treating breast cancer and preparation method thereof |
| CN104758464A (en) * | 2015-03-16 | 2015-07-08 | 徐若曾 | Blood-activating and stasis-resolving medicament for treating breast cancer and preparation method thereof |
| CN105326975A (en) * | 2015-12-04 | 2016-02-17 | 钱玲科 | Traditional Chinese medicine extract and application of same to preparation of drug for treating cervical carcinoma |
| CN106362114A (en) * | 2016-10-13 | 2017-02-01 | 南宁多灵生物科技有限公司 | Medicine for treating breast cancer |
| CN106729158A (en) * | 2017-02-21 | 2017-05-31 | 上海世道健康科技有限公司 | It is a kind of to treat Chinese medicine composition of osteocarcinoma and preparation method thereof |
| CN111184835A (en) * | 2020-04-09 | 2020-05-22 | 喻小兰 | A pharmaceutical composition prepared from baicalein for treating cervical cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103919887B (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103919887B (en) | A kind of Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN103040924A (en) | Radix millettiae speciosae extract and application thereof in preparing drugs for treating osteoporosis | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN104338043A (en) | Medicament for improving immunity and preparation method thereof | |
| CN104436018A (en) | Medicine for treating tumors and preparation method thereof | |
| CN102000164B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN103599495A (en) | Chinese medicinal composition for treatment of hepatitis B | |
| CN103705687A (en) | Traditional Chinese medicinal composition for preventing and treating early chronic renal failure and preparation method thereof | |
| CN104984267A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN104435686A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating skin itch and eczema papulosum | |
| CN104173950A (en) | Chinese herbal medicine composition for treating prostatic cancer | |
| CN105999113A (en) | Traditional Chinese medicine composition for treating intractable insomnia and preparation method thereof | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN104208358A (en) | Traditional Chinese medicine for treating renal calculi | |
| CN103565987A (en) | Traditional Chinese medicine powder for treating silky coccidiosis | |
| CN105250588A (en) | Chinese herbal preparation for treating kidney failure and preparation method of Chinese herbal preparation | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN103550608B (en) | Traditional Chinese medicine for treating liver-stagnation and spleen-deficiency syndrome type hypomenorrhea | |
| CN106214905A (en) | A kind of Chinese medicine composition treating mastitis and preparation method thereof | |
| CN105288173A (en) | Traditional Chinese medicine pellet preparation for regulating menstruation and removing freckles and preparation method thereof | |
| CN104435231A (en) | Method for preparing medicine preparation named Fangfengtongsheng | |
| CN104645247B (en) | A kind of Chinese medicine preparation for treating hepatolenticular degeneration and preparation method thereof | |
| CN111603501B (en) | Traditional Chinese medicine composition for primary liver cancer and application thereof | |
| CN103272107B (en) | A kind of Chinese medicine composition of nursing for treating icterohepatitis | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Fu Dezhao Inventor before: Fu Lijia Inventor before: Fu Jianjia Inventor before: Ma Jun Inventor before: Zhao Minzi |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FU LIJIA FU JIANJIA MA JUN ZHAO MINZI TO: FU DEZHAO |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |